Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
BCAX
Upturn stock ratingUpturn stock rating

Bicara Therapeutics Inc. Common Stock (BCAX)

Upturn stock ratingUpturn stock rating
$11.41
Last Close (24-hour delay)
Profit since last BUY-3.39%
upturn advisory
WEAK BUY
BUY since 14 days
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/14/2025: BCAX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

7 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $32.6

1 Year Target Price $32.6

Analysts Price Target For last 52 week
$32.6 Target price
52w Low $7.8
Current$11.41
52w High $28.09

Analysis of Past Performance

Type Stock
Historic Profit -50.41%
Avg. Invested days 13
Today’s Advisory WEAK BUY
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 1.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/14/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 622.56M USD
Price to earnings Ratio -
1Y Target Price 32.6
Price to earnings Ratio -
1Y Target Price 32.6
Volume (30-day avg) 7
Beta -
52 Weeks Range 7.80 - 28.09
Updated Date 08/15/2025
52 Weeks Range 7.80 - 28.09
Updated Date 08/15/2025
Dividends yield (FY) -
Basic EPS (TTM) -4.66

Earnings Date

Report Date 2025-08-12
When -
Estimate -0.5367
Actual -0.5

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -22.85%
Return on Equity (TTM) -32.71%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 188194015
Price to Sales(TTM) -
Enterprise Value 188194015
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -
Shares Outstanding 54562800
Shares Floating 26351124
Shares Outstanding 54562800
Shares Floating 26351124
Percent Insiders 12.23
Percent Institutions 99.84

ai summary icon Upturn AI SWOT

Bicara Therapeutics Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Bicara Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing dual-action biologics that combine the precision of antibodies with the power of TLR agonists to drive potent and durable anti-tumor responses. Founded in 2018, they're advancing a pipeline of novel therapies designed to address unmet needs in cancer treatment.

business area logo Core Business Areas

  • Oncology Therapeutics Development: Developing and commercializing novel dual-action biologics for cancer treatment.
  • Antibody Engineering: Engineering novel antibodies with enhanced specificity and efficacy.
  • TLR Agonist Technology: Utilizing TLR agonists to stimulate the immune system to fight cancer.

leadership logo Leadership and Structure

The leadership team includes experienced professionals in drug development, clinical trials, and business development. The company's structure is typical of a biotech firm, with departments focused on research, development, clinical operations, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • BCA101: A bifunctional antibody targeting EGFR and engaging TLR9, currently in clinical trials for advanced solid tumors. Market share data is not yet available due to its clinical stage. Competitors include companies developing EGFR inhibitors and TLR9 agonists.
  • Pipeline Programs: Other preclinical programs targeting various cancer pathways. Market share data is not available for preclinical programs. Competitors include companies developing similar therapeutics for specific cancer indications.

Market Dynamics

industry overview logo Industry Overview

The oncology therapeutics market is large and growing, driven by an increasing incidence of cancer and advancements in treatment options. Immunotherapy and targeted therapies are major areas of innovation.

Positioning

Bicara Therapeutics is positioned as an innovator in the field of dual-action biologics for cancer. Their competitive advantage lies in their proprietary technology platform that combines antibody specificity with TLR agonist stimulation.

Total Addressable Market (TAM)

The TAM for cancer therapeutics is estimated to be hundreds of billions of dollars. Bicara is positioned to capture a portion of this market by developing differentiated therapies that address unmet needs.

Upturn SWOT Analysis

Strengths

  • Novel technology platform
  • Experienced management team
  • Promising preclinical and clinical data
  • Strong intellectual property position

Weaknesses

  • Early-stage company
  • Limited financial resources
  • High risk of clinical trial failure
  • Dependence on key personnel

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion of pipeline into new indications
  • Positive clinical trial results
  • Market demand for innovative cancer therapies

Threats

  • Competition from established pharmaceutical companies
  • Regulatory hurdles
  • Changes in reimbursement policies
  • Unexpected adverse events in clinical trials

Competitors and Market Share

competitor logo Key Competitors

  • MRTX
  • LLY
  • REGN

Competitive Landscape

Bicara's dual-action approach offers a potential advantage over single-target therapies. However, it faces competition from larger companies with more resources and established market presence.

Growth Trajectory and Initiatives

Historical Growth: Historical growth data not available, as it's an early-stage company.

Future Projections: Future growth is dependent on clinical trial success and potential partnerships. Analyst estimates are not available.

Recent Initiatives: Focusing on advancing BCA101 through clinical trials and expanding pipeline with new dual-action biologics.

Summary

Bicara Therapeutics is a clinical-stage biopharmaceutical company with a novel dual-action biologic platform that shows promise in oncology. The company's technology and management team are key strengths. The main challenges are clinical trial success and competition. Securing partnerships is vital to its growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Bicara Therapeutics' Website
  • SEC Filings
  • Industry Reports

Disclaimers:

The data and analysis provided are for informational purposes only and should not be considered investment advice. Investment decisions should be based on independent research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Bicara Therapeutics Inc. Common Stock

Exchange NASDAQ
Headquaters Boston, MA, United States
IPO Launch date 2024-09-13
CEO & Director Dr. Claire Mazumdar Clemon M.B.A., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 55
Full time employees 55

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody with a domain that binds to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.